Linking metabolic reprogramming to therapy resistance in cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1868, Issue 1, 2017, Pages 1-6

  Morandi, Andrea ^a   Indraccolo, Stefano ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Metabolic reprogramming; OXPHOS; Therapy resistance; Warburg metabolism

Indexed keywords

ALANINE; AROMATASE INHIBITOR; AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; CISPLATIN; DICHLOROACETIC ACID; DOXORUBICIN; ESTROGEN RECEPTOR; FULVESTRANT; GAMMA SECRETASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTIC ACID; MITOCHONDRIAL DNA; MONOCARBOXYLATE TRANSPORTER 4; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TAMOXIFEN; TRASTUZUMAB; VASCULOTROPIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; COLON CANCER; DNA ADDUCT; GLIOBLASTOMA; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HYPOXIA; LIVER CELL CARCINOMA; METABOLIC REPROGRAMMING; METABOLISM; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; REVIEW; ANIMAL; CELL TRANSFORMATION; DRUG RESISTANCE; NEOPLASM; NUCLEAR REPROGRAMMING; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; DRUG RESISTANCE, NEOPLASM; GLYCOLYSIS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; OXIDATIVE PHOSPHORYLATION;

EID: 85009724113     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2016.12.004     Document Type: Review

References (59)

1. [1] Sakai, W., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:7182 (2008), 1116–1120.
2. [2] Ozben, T., Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580:12 (2006), 2903–2909.
3. [3] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:5930 (2009), 1029–1033.
4. [4] Xu, R.H., et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65:2 (2005), 613–621.
5. [5] Wagner, W., Ciszewski, W.M., Kania, K.D., L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation. Cell Commun. Signal., 13, 2015, 36.
6. [6] Botzer, L.E., et al. Hexokinase 2 is a determinant of neuroblastoma metastasis. Br. J. Cancer 114:7 (2016), 759–766.
7. [7] Khiati, S., et al. Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clin. Cancer Res. 20:18 (2014), 4873–4881.
8. [8] Jones, R.L., Swanton, C., Ewer, M.S., Anthracycline cardiotoxicity. Expert Opin. Drug Saf. 5:6 (2006), 791–809.
9. [9] Yen, H.C., et al. Enhancement of cisplatin-induced apoptosis and caspase 3 activation by depletion of mitochondrial DNA in a human osteosarcoma cell line. Ann. N. Y. Acad. Sci. 1042 (2005), 516–522.
10. [10] Qian, W., et al. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am. J. Physiol. Cell Physiol. 289:6 (2005), C1466–C1475.
11. [11] Zhao, J.G., Ren, K.M., Tang, J., Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism. Tumour Biol. 35:12 (2014), 12305–12315.
12. [12] Ma, S., et al. Targeting cellular metabolism chemosensitizes the doxorubicin-resistant human breast adenocarcinoma cells. Biomed. Res. Int., 2015, 2015, 453986.
13. [13] Wojtkowiak, J.W., et al. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol. Pharm. 8:6 (2011), 2032–2038.
14. [14] Vukovic, V., Tannock, I.F., Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 75:8 (1997), 1167–1172.
15. [15] Gerweck, L.E., Vijayappa, S., Kozin, S., Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 5:5 (2006), 1275–1279.
16. [16] Giannoni, E., et al. Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. Oncotarget 6:27 (2015), 24061–24074.
17. [17] Viale, A., et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514:7524 (2014), 628–632.
18. [18] Matassa, D.S., et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 23:9 (2016), 1542–1554.
19. [19] Vellinga, T.T., et al. SIRT1/PGC1α-dependent increase in oxidative phosphorylation supports chemotherapy resistance of colon cancer. Clin. Cancer Res. 21:12 (2015), 2870–2879.
20. [20] Ippolito, L., et al. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. Oncotarget, 2016.
21. [21] Zhou, Y., et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 72:1 (2012), 304–314.
22. [22] Sancho, P., Barneda, D., Heeschen, C., Hallmarks of cancer stem cell metabolism. Br. J. Cancer 114:12 (2016), 1305–1312.
23. [23] Martinez-Outschoorn, U.E., Lisanti, M.P., Sotgia, F., Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 25 (2014), 47–60.
24. [24] Fiaschi, T., et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 72:19 (2012), 5130–5140.
25. [25] Fong, M.Y., et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17:2 (2015), 183–194.
26. [26] Bovenzi, C.D., et al. Prognostic indications of elevated MCT4 and CD147 across cancer types: a meta-analysis. Biomed. Res. Int., 2015, 2015, 242437.
27. [27] Bacci, M., et al. miR-155 drives metabolic reprogramming of ER + breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Cancer Res., 2016.
28. [28] Doyen, J., et al. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem. Biophys. Res. Commun. 451:1 (2014), 54–61.
29. [29] Fribbens, C., et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 34:25 (2016), 2961–2968.
30. [30] Alluri, P.G., Speers, C., Chinnaiyan, A.M., Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res., 16(6), 2014, 494.
31. [31] Morandi, A., et al. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res. 73:12 (2013), 3783–3795.
32. [32] Woo, Y.M., et al. Inhibition of aerobic glycolysis represses Akt/mTOR/HIF-1α axis and restores tamoxifen sensitivity in antiestrogen-resistant breast cancer cells. PLoS One, 10(7), 2015, e0132285.
33. [33] Martinez-Outschoorn, U.E., et al. Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle 10:15 (2011), 2521–2528.
34. [34] Morandi, A., Chiarugi, P., Metabolic implication of tumor:stroma crosstalk in breast cancer. J. Mol. Med. (Berl.) 92:2 (2014), 117–126.
35. [35] Sansone, P., et al. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat. Commun., 7, 2016, 10442.
36. [36] Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8:8 (2008), 592–603.
37. [37] McIntyre, A., Harris, A.L., Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol. Med. 7:4 (2015), 368–379.
38. [38] Curtarello, M., et al. VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells. Cancer Res. 75:1 (2015), 120–133.
39. [39] Allen, E., et al. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep. 15:6 (2016), 1144–1160.
40. [40] Jimenez-Valerio, G., et al. Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients. Cell Rep. 15:6 (2016), 1134–1143.
41. [41] Pisarsky, L., et al. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep. 15:6 (2016), 1161–1174.
42. [42] Perez-Escuredo, J., et al. Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. Cell Cycle 15:1 (2016), 72–83.
43. [43] Quintieri, L., Selmy, M., Indraccolo, S., Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications. Biochem. Pharmacol. 89:2 (2014), 162–170.
44. [44] Davidson, S.M., et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23:3 (2016), 517–528.
45. [45] Pavlova, N.N., Thompson, C.B., The emerging hallmarks of cancer metabolism. Cell Metab. 23:1 (2016), 27–47.
46. [46] Rapisarda, A., Melillo, G., Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist. Updat. 12:3 (2009), 74–80.
47. [47] Shen, Y.C., et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br. J. Cancer 108:1 (2013), 72–81.
48. [48] McIntyre, A., et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin. Cancer Res. 18:11 (2012), 3100–3111.
49. [49] Eichner, R., et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat. Med. 22:7 (2016), 735–743.
50. [50] Granchi, C., Minutolo, F., Anticancer agents that counteract tumor glycolysis. ChemMedChem 7:8 (2012), 1318–1350.
51. [51] Martinez-Outschoorn, U.E., et al. Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol., 2016.
52. [52] Mancuso, M.R., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116:10 (2006), 2610–2621.
53. [53] Keunen, O., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 108:9 (2011), 3749–3754.
54. [54] Sounni, N.E., et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 20:2 (2014), 280–294.
55. [55] Bensaad, K., et al. Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 9:1 (2014), 349–365.
56. [56] Sengupta, D., Pratx, G., Imaging metabolic heterogeneity in cancer. Mol. Cancer, 15, 2016, 4.
57. [57] Zhao, Y., et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 71:13 (2011), 4585–4597.
58. [58] Hudson, C.D., et al. Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell Death Dis., 5, 2014, e1160.
59. [59] Herranz, D., et al. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat. Med. 21:10 (2015), 1182–1189.